Visual and oculomotor disorders in patients with multiple sclerosis in connection with comorbidity
ARTICLE PDF (Українська)

Keywords

multiple sclerosis, comorbidity, visual, oculomotor disorders, acupuncture

How to Cite

Chupryna, G. (2016). Visual and oculomotor disorders in patients with multiple sclerosis in connection with comorbidity. East European Journal of Neurology, (3(9), 12-17. https://doi.org/10.33444/2411-5797.2016.3(9).12-17

Abstract

Conducted study visual and oculomotor disorders in patients with multiple sclerosis (MS) to identify the features of their occurrence and determination due to the performance quality of life, level of fatigue, depression, pain, cognitive impairment in terms of comorbidity. It examined 207 patients with different forms of MS course. The average prevalence of visual impairment in our studied patients with MS was 56.0% and -81.2% oculomotor disorders. It was found that in patients with MS comorbidity, visual disturbances and oculomotor disorders have greater prevalence and severity. The severity of visual disorders are closely correlated (p <0.05) with the level of depression and cognitive impairment, and the severity of the eye disorders - fatigue level of p <0.05.

https://doi.org/10.33444/2411-5797.2016.3(9).12-17
ARTICLE PDF (Українська)

References

1. Color vision isstrongly associated with retinal thinning in multiple sclerosis/ Villoslada P., Cuneo A., Gelfand J. [et al.]// Mult Scler J 2012.- Vol. 18.- P.991–999.
2. Costello F. The afferent visual pathway: designing a structural-functional paradigm of multiple sclerosis / Costello F. // ISRN Neurol 2013.-2013:134858.
3. Dynamics of saccade parameters in multiple sclerosis patients with fatigue/ Finke C, Pech LM, Sommer C, [et al.]// . J Neurol.- 2012.- Vol. 259.- Р. 2656–2663.
4. Impact of visual impairment on health-related quality of life in multiple sclerosis/ Pawar VS, Pawar G, Miller L-A [et al.]// Int J MS Care.- 2010.- Vol.12.- Р. 83–91.
5. Low-contrast acuity measures visual improvement in phase 3 trial of natalizumab in relapsing / Balcer LJ, Galetta SL, PolmanCH, [et al.]// MS. J Neurol Sci.- 2012.- Р.119–124.
6. Low contrast visual acuity testing is associated with cognitive performance in multiple sclerosis: a cross-sectional pilot study/ Wieder L, Gade G, Pech LM, [et al.]// . BMC Neurol .-2013.- Vol. 13.-Р. 167.
7. Optic Neuritis Study Group (2008). Visual Function 15 Years after Optic Neuritis: A Final Follow-up Report from the Optic Neuritis Treatment Trial. Ophthalmology 115(6): 1079-1082.e5
8. Persistent visual impairment in multiple sclerosis: prevalence,mechanisms and resulting disability /Jasse L., Vukusic S., Durand-Dubief F.[et al.]// Mult Scler J.- 2013.- Vol.19.- P.1618–1626.
9. Risk of cataract and glaucoma in patients with multiple sclerosis/ Bazelier MT, Mueller-Schotte S, Leufkens HG [et al.]// Mult Scler.- 2012.- Vol. 18.- Р.628–638.
10. Rougier M.-B. Les troubles oculomoteurs au cours de la sclérose en plaques/ Rougier M.-B., Tilikete C.// Journal Français d'Ophtalmologie.-2008.- Vol.31.-№7.- 717-721.
11. Treatment of corticosteroid refractory optic neuritis in multiple sclerosis patients with intravenous immunoglobulin / Tselis A, Perumal J, Caon C, [et al.]// Eur J Neurol 2008.- Vol. 15.-Р. 1163–1167.
12. Treatment of steroid-unresponsive optic neuritis with plasma exchange/ Roesner S, Appel R, Gbadamosi J, Martin R, Heesen C.// Acta Neurol Scand.- 2012.- Vol.126.- Р. 103–108.
13. Vision and vision-related outcome measures in multiple sclerosis / Balcer L. J., Miller D.H., Reingold S.C. [et al.]// BRAIN .- 2015.- Vol. 138.- P. 11–27.
14. Vision in a Phase 3 Trial of Natalizumab for MultipleSclerosis: Relation to Disability and Quality of Life/ Chahin S., Balcer L. J., Miller D. M. [et al.]// J Neuro-Ophthalmol 2015; 35: 6-11